Nykode Therapeutics AS (OSL:NYKD)
Norway · Delayed Price · Currency is NOK 3.240
-0.030 (-0.92%)
Jun 4, 2026, 10:59 AM CET
Nykode Therapeutics AS Company Description
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases.
The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial.
It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code.
Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Nykode Therapeutics AS
| Country | Norway |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Michael Engsig |
Contact Details
Address: Oslo Science Park Oslo, 0349 Norway | |
| Phone | 47 22 95 81 93 |
| Website | nykode.com |
Stock Details
| Ticker Symbol | NYKD |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | NO0010714785 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael Thyring Engsig | Chief Executive Officer |
| Dr. Agnete B. Fredriksen Ph.D. | Co-Founder and Chief Scientific Officer |
| Harald Gurvin | Chief Financial Officer |
| Louise Stubbe | Chief Legal Officer |